There are currently 1005 clinical trials in San Antonio, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Health Science Center at San Antonio, GSK Investigational Site, Pfizer Investigational Site and Methodist Children's Hospital of South Texas. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Artisan Aphakia Lens for the Correction of Aphakia (Secondary) in Adults
NCT01547429
Recruiting
This study will determine the safety and effectiveness of the Artisan Aphakia Lens when used as a secondary implant to correct aphakia in adults.
Gender:
All
Ages:
22 years and above
Trial Updated:
06/24/2022
Locations: Focal Point Vision, San Antonio, Texas
Conditions: Aphakia
Register for Updates
CSD201001: Study to Assess Elements of Abuse Liability for Three Nicotine Pouches
NCT05129657
Recruiting
This is a two-site, open-label, randomized, 5-way cross-over study designed to evaluate elements of abuse liability (AL) including subjective effects and physiological measures (pharmacodynamics [PD]) and plasma nicotine uptake (pharmacokinetics [PK]) during and following ad libitum use of the study investigational products (IPs) by generally healthy smokers.
Gender:
All
Ages:
Between 21 years and 60 years
Trial Updated:
06/23/2022
Locations: ICON Clinical Research, San Antonio, Texas
Conditions: Smoking, Tobacco Use, Tobacco Smoking
Register for Updates
A Study of Injection HB0025 in Patients With Advanced Solid Tumors
NCT04678908
Recruiting
This is a multicenter, open-label, dose escalation and expansion study. During the study, subjects will be evaluated for safety, toxicity, tolerability, PK/PD, immunogenicity, biomarkers, and antitumor activity of HB0025. The phase I study will enroll up to 154 subjects with advanced solid tumors who have progressed on or after standard of care therapy and for whom there is no further treatment available that in the judgement of the patient's physician would be beneficial. One cycle is defined a... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2022
Locations: NEXT Oncology, San Antonio, Texas
Conditions: Tumor, Subjects
Register for Updates
Evaluation of EpiBone-CMF for Mandibular Ramus Reconstruction
NCT03678467
Recruiting
EpiBone-Craniomaxillofacial (EB-CMF) is an autologous, anatomically shaped bone graft created specifically for the patient's defect, using the patients own adipose-derived mesenchymal stem cells. This first in human trial is designed specifically to assess the safety of EB-CMF clinically. Although secondary measures of graft efficacy are being assessed, the primary focus will be on Adverse Events stemming from graft implantation.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/24/2022
Locations: UT Health San Antonio, San Antonio, Texas
Conditions: Mandible Tumor, Mandibular Injuries, Mandible; Deformity
Register for Updates
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
NCT04857359
Recruiting
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
05/18/2022
Locations: UT Health Science Center, San Antonio, San Antonio, Texas
Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Register for Updates
A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata
NCT05205070
Recruiting
Efficacy and safety of rosnilimab (ANB030) in subjects with moderate-to-severe Alopecia Areata
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/03/2022
Locations: Site 10-108, San Antonio, Texas
Conditions: Alopecia Areata
Register for Updates
Study of Endothelial Cell Condition After Cataract Surgery Performed Using Capsulorhexis or ZEPTO
NCT04882189
Recruiting
This study will use images of the subjects' corneal endothelium obtained using non-invasive specular microscopy to obtain corneal endothelial cell density, the coefficient of variation in endothelial cell size, and the percentage of hexagonal endothelial cells following routine cataract surgery performed using the standard method of manual capsulorhexis compared to cataract surgery performed using Zepto Precision Capsulotomy System.
Gender:
All
Ages:
50 years and above
Trial Updated:
03/08/2022
Locations: UltraVision, San Antonio, Texas
Conditions: Endothelial Cell Density Loss
Register for Updates
A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers
NCT05279755
Recruiting
This trial is a Phase 1a/1b, randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of prosetin administered to healthy adult subjects.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/06/2022
Locations: Worldwide Clinical Trials Early Phase Services, San Antonio, Texas
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Pilot Study: KeraStat® Gel for Topical Delivery of Morphine for Management of Non-Healing, Painful Open Wounds and Ulcers
NCT05217160
Recruiting
This study is intended to provide information from subjects who currently have painful, chronically open wounds and assess the pain reduction capacity of KeraStat® Gel with Morphine. In gathering data from subjects who have baseline pain from their chronically open wounds, the investigators can then evaluate the capacity of KeraStat® Gel plus Morphine in reducing the subjects daily pain levels, pain associated with dressing changes, and pain medication consumption.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/19/2022
Locations: South Texas Aesthetic and Reconstructive Surgery, San Antonio, Texas
Conditions: Wound of Skin, Burns
Register for Updates
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
NCT02675946
Recruiting
This is a multicenter, open-label study conducted in two phases: Phase 1 consisting of a CGX1321 Single Agent Dose Escalation Phase in solid tumors, CGX1321 Single Agent Dose Expansion Phase in GI tumors and Roll-over Cohort of CGX1321 and pembrolizumab in subjects who have progressed on single agent CGX1321 and Phase 1b consisting of CGX1321 in combination with pembrolizumab in colorectal tumors and CGX1321 in combination with encorafenib + cetuximab in BRAFV600E mutated colorectal tumors. Both... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/11/2022
Locations: START (South Texas Accelerated Research Therapeutics, LLC), San Antonio, Texas
Conditions: Solid Tumors, GI Cancer
Register for Updates
Sample Collection Study for the CellMax Life Circulating Tumor Cell and Circulating Tumor DNA Platforms for the Early Detection of Colorectal Cancer and Adenomas
NCT05127096
Recruiting
The purpose of this study is to collect clinical specimens from subjects with a diagnosis of colorectal cancer/advanced adenoma or undergoing a screening colonoscopy and meeting study eligibility criteria.
Gender:
All
Ages:
Between 45 years and 80 years
Trial Updated:
11/09/2021
Locations: CellMax Site H, San Antonio, Texas
Conditions: Colorectal Cancer Screening
Register for Updates
A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors
NCT04859777
Recruiting
This is a Phase 1/1b open-label, dose-escalation, and cohort expansion study with BID (tablet) oral dose of MPT-0118 in subjects with advanced or metastatic refractory solid tumors. The study will be conducted in 3 parts: Part A: MPT-0118 dose-escalation Part B: MPT-0118 dose-escalation in combination with pembrolizumab Part C: Cohort expansion of MPT-0118 in combination with pembrolizumab
Gender:
All
Ages:
18 years and above
Trial Updated:
09/15/2021
Locations: NEXT Oncology, San Antonio, Texas
Conditions: Solid Tumor, Adult, Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Refractory Cancer
Register for Updates